MedTrace Logo

Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT

NCT06230770 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2025-07-09

No results posted yet for this study

Summary

Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.

Conditions

  • Gender
  • Contraception

Interventions

BEHAVIORAL

Bleeding data

Participants will report their daily bleeding patterns

Sponsors & Collaborators

Principal Investigators

  • Kelsey Loeliger, MD. PhD · UC San Diego

  • Sarah Averbach, MD, MSc · UC San Diego

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-06-10
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06230770 on ClinicalTrials.gov